Sangamo Therapeutics, Inc.
Artifical nucleases comprising engineered cleavage half-domains
Last updated:
Abstract:
Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
Status:
Grant
Type:
Utility
Filling date:
2 Apr 2020
Issue date:
5 Oct 2021